191 results on '"Shames, D."'
Search Results
2. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project
3. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
4. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer
5. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer
6. Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: formulating recommendations in an environment of evolving clinical science
7. Dynamische, kontrastverstärkte (DCE-) MRI mit makromolekularem Kontrastmittel zur nicht-invasiven Differenzierung von Tumoren mit hoher, von Tumoren mit niedriger intrinsischer VEGF-Aktivität am experimentellen Tumormodell: PO576
8. Pulmonary oxygen toxicity: Demonstration of abnormal capillary permeability using contrast-enhanced MRI
9. P22.02 Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease
10. MA07.02 Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150
11. OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
12. 1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
13. LBA81_PR - Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
14. 1559P - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK study
15. MA03.05 BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer
16. 85P - Dissecting gastric cancer biology and how and when to use immunotherapy
17. P1.04-011 Development of Novel Blood-Based Biomarker Assays in 1L Advanced/Metastatic NSCLC: Blood First Assay Screening Trial (BFAST)
18. MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
19. 196P - Prevalence, Prognostic Significance, and Overlap of Actionable Biomarkers in Nsclc
20. 194P - Prevalence and Prognostic Significance of Sodium-Dependent Phosphate Transporter 2B (Napi2B) Protein Expression in Non-Small Cell Lung Cancer (Nsclc)
21. NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition.
22. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers.
23. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.
24. Accuracy of simple techniques for estimating fractional zinc absorption in humans.
25. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model.
26. A new polysaccharide macromolecular contrast agent for MR imaging: biodistribution and imaging characteristics.
27. Tumor blood volume assays using contrast-enhanced magnetic resonance imaging: regional heterogeneity and postmortem artifacts.
28. Comparison of albumin-(Gd-DTPA)30 and Gd-DTPA-24-cascade-polymer for measurements of normal and abnormal microvascular permeability.
29. Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
30. Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium.
31. Two-Detector, 512-Element High Purity Germanium Camera Prototype.
32. A Multi-Wire Proportional Chamber for Nuclear Medicine Applications.
33. PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC.
34. Mapping Abnormal Synovial Vascular Permeability in Temporomandibular Joint Arthritis in the Rabbit Using MRI.
35. MA04.10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC.
36. The double isotope tracer method is a reliable measure of fractional zinc absorption.
37. DNA methylation-associated inactivation of TGFβ-related genes, DRM/Gremlin, RUNX3, and HPP1 in human cancers.
38. Iodipamide Kinetics in die Dog: A Multicompartmental Analysis.
39. CMR 2007: 2.02: Characterizing cancer microvasculature: correlations of dynamic macromolecular contrast media-enhanced MRI with microscopic morphology.
40. CMR 2007: 2.04: Novel macromolecular iodinated contrast medium permits assays of cancer microvascular leakiness in response to anti-VEGF antibody using dynamic CT.
41. CMR 2007: 7.01: Development of new dendrimeric MRI contrast agents with poly(ethylene glycol) cores: toward the selection of the single best compound.
42. CMR 2005: 3.01: MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctylmannose conjugate (Gadofluorine M), a novel protein-avid contrast agent.
43. Evaluation of ethanol hypoglycemia in man: Turnover studies with C-6 14C glucose
44. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
45. 85PDissecting gastric cancer biology and how and when to use immunotherapy.
46. 1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC.
47. LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC).
48. Gallium-67 uptake in silent myocardial infarction: a case report
49. Impact of nuclear medicine on the diagnosis and management of cardiovascular disease
50. Hazards in interpretation of xenon washout studies of the canine kidney
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.